You are here: Industry Insights > AbbVie

News List

AbbVie and Calibr partner to develop T-cell therapies for cancer pharmaceutical-technology
June 28, 2018
AbbVie has formed an alliance with Scripps Research’s non-profit drug discovery unit Calibr to develop next-generation T-cell therapies that are aimed at targeting various cancers, including solid tumours.
AbbVie unveils high undetectable disease rates for venetoclax/rituximab combo pharmatimes
June 21, 2018
AbbVie has unveiled new data showing high and durable undetectable minimal residual disease rates in patients with chronic lymphocytic leukaemia treated with venetoclax in combination with rituximab.
AbbVie slammed by FDA for improper handling of Humira death complaints fiercepharma
June 13, 2018
A number of AbbVie products coming out of its North Chicago, Illinois, manufacturing facility have been tied to death complaints,including its mammoth blockbuster Humira...
Up-and-coming Pfizer, AbbVie drugs set to threaten Amgen, Celgene fiercepharma
May 30, 2018
With Pfizer’s Xeljanz snapping up new indications and AbbVie’s upadacitinib on the way, makers of anti-inflammatory drugs will soon feel the heat from JAK inhibitors if they haven't already. But some will feel it more than others, Bernstein analysts say.
AbbVie makes good on charity promise with $100M donation for Puerto Rico relief fiercepharma
May 28, 2018
AbbVie is one of the biggest biopharma beneficiaries of U.S. tax reform. Besides spending the extra savings on new projects, shareholder returns and pension funds, the company has also decided to give a substantial amount to support charities in Puerto Ri
AbbVie eyes Imbruvica expansion in CLL as Gazyva pairing hits its marks fiercepharma
May 28, 2018
AbbVie’s Imbruvica growth strategy in chronic lymphocytic leukemia centers on expanding use of the drug among previously untreated patients. And it now has some new data that should help it do that.
EMA review confirms risks of Abbvie and Biogen's Zinbryta outweigh benefits pharmafile
May 25, 2018
The EMA has judged that the benefits offered by Zinbryta (daclizumab), Abbvie and Biogen’s humanised IgG1 monoclonal antibody for the treatment of multiple sclerosis (MS), do not outweigh its risks, following a review carried out by the agency’s Pharmacov
Up-and-coming Pfizer, AbbVie drugs set to threaten Amgen, Celgene fiercepharma
May 23, 2018
With Pfizer’s Xeljanz snapping up new indications and AbbVie’s upadacitinib on the way, makers of anti-inflammatory drugs will soon feel the heat from JAK inhibitors if they haven't already. But some will feel it more than others, Bernstein analysts say.
AbbVie files risankizumab in the US pharmatimes
April 28, 2018
AbbVie has filed risankizumab in the US seeking approval for its use to treat moderate-to-severe plaque psoriasis.
Strong Sales of Humira, Imbruvica and HCV Drug Mavyret Drive AbbVie’s Strong First Quarter biospace
April 28, 2018
Humira, the world’s best-selling drug, keeps on churning out positive sales results for AbbVie, despite looming challenges.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page